Acadia Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Acadia Pharmaceuticals Inc's ROI in the second quarter of 2026?
Acadia Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 31.05 % in its second quarter of 2026, this is above ACAD's average return on investment of -35.06%.
Acadia Pharmaceuticals Inc invested over the 12 months ending in its second quarter of 2026 $1,225 million

ROI fell compared to the first quarter of 2026, despite the net income growth of 766.1% from the first quarter of 2026.

Within the Healthcare sector 31 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 151, from total ROI ranking in the first quarter of 2026 at 160.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	55.52 %	55.9 %	56.14 %	56.73 %	56.12 %
Y / Y Net Income Change TTM	71.27 %	64.12 %	86.28 %	294.8 %	565.37 %
Investment (TTM) in Millions	1,381	1,300	1,246	974	896
Return On Investment (TTM)	31.05 %	34.03 %	39.64 %	29.91 %	28.2 %
ACAD's Overall Ranking	# 151	# 160	# 0	# 174	# 135
Seq. Investment Change TTM	11.01 %	11.91 %	12.96 %	10.83 %	11.27 %
Seq. Net Income Change TTM	1.29 %	-3.93 %	49.71 %	17.56 %	-2.94 %
Net Income (TTM) in Millions	380	376	391	261	222

ACAD Company Profile >> Back to ACAD Roi Comparisons >> See Annual ACAD Return On Investment

Return On Investment ACAD's Ranking
Within:	No.
Industry	# 16
Sector	# 32
Overall	# 151

Return On Investment Statistics
High	Average	Low
39.64 %	-35.06 %	-98.15 %
(Dec 31 2025)		(Sep 30 2012)

News about Acadia Pharmaceuticals Inc Return on Investment ROI

Acadia Pharmaceuticals Leading the Charge in Rett Syndrome Treatment and Financial Performance,

October 16, 2024

Acadia Pharmaceuticals: Pioneering Advances in Rett Syndrome Treatment Amid Financial GrowthAcadia Pharmaceuticals Inc. a biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, has made significant strides in both clinical achievements and financial performance. Recently, the company announced that Health Canada granted marketing authorization for DAYBUE (trofinetide) for the treatment of Rett syndrome, making it the first and only drug approved in Canada specifically for this rare neurodevelopmental disorder. This approval, achieved through the Priority Review process, underscores Acadia s commitment to addressing unmet medical needs in complex conditions affecting both adult and pediatric patients aged two years and older.Rett syndrome is a genetic condition primarily affecting girls and is characterized by normal early development followed by a loss of acquired skills. This condition results in various challenges, including difficulties with speech, movement, and cognitive function. With the approval of DAYBUE, Acadia Pharmaceuticals not only provides a potential treatment option for patients and their families but also demonstrates the importance of developing targeted therapies for rare diseases.

Financial Statements
Acadia Pharmaceuticals Inc's II. Quarter Investments	$ 1,381 Millions	ACAD's Balance sheet
Acadia Pharmaceuticals Inc's II. Quarter Income	$ 32 Millions	Quarterly ACAD's Income Statement
ACAD's Income by Division		See ACAD's Income by Division

ACAD Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	1,287	793	495	462	604
Y / Y Investment Growth	62.33 %	60.28 %	7.04 %	-23.49 %	-10.73 %
Net Income in Millions	391	226	-61	-216	-168
Y / Y Net Income Growth	72.66 %	-	-	-	-
Annual Return On Investment	30.38 %	28.56 %	-12.39 %	-46.73 %	-27.79 %

Annual Roi Comment

In the fiscal year 2025 ROI improved to 30.38 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ACAD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ACAD's Competitors
Subscribers only: Roi for Acadia Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ACAD's Customers

Other Ratios
ACAD's Roa	ACAD's Inventory Turnover Ratio	ACAD's Growth Rates	ACAD's Dividend Statistics
	ACAD's Profitability Ratios	ACAD's Asset Turnover Ratio	ACAD's Dividend Growth
ACAD's Roe	ACAD's Valuation Ratios	ACAD's Financial Strength Ratios	ACAD's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Actinium Pharmaceuticals Inc	84.38 %
Exelixis Inc	82.05 %
Lensar Inc	75.31 %
Ironwood Pharmaceuticals inc	70.54 %
Oramed Pharmaceuticals Inc	68.90 %
Indivior Pharmaceuticals Inc	68.79 %
Rallybio Corporation	68.28 %
Fortress Biotech Inc	68.27 %
Earth Science Tech Inc	64.38 %
Meiragtx Holdings Plc	55.83 %
Elite Pharmaceuticals Inc	53.48 %
Idexx Laboratories Inc	51.80 %
Aurinia Pharmaceuticals Inc	50.35 %
Qhslab Inc	48.94 %
Q32 Bio Inc	47.43 %
Vaxart Inc	46.17 %
Liquidia Corporation	42.09 %
Tg Therapeutics Inc	39.26 %
Medpace Holdings Inc	35.54 %
Mettler toledo International Inc	34.41 %
Eli Lilly And Company	33.95 %
Acadia Pharmaceuticals Inc	31.05 %
Caredx Inc	29.42 %
Adma Biologics Inc	28.94 %
Protalix Biotherapeutics inc	25.72 %
Pro dex Inc	24.29 %
Innoviva Inc	23.33 %
Electromed Inc	23.18 %
Zevra Therapeutics Inc	22.90 %
Iradimed Corporation	22.57 %

Date modified: 2026-09-11T09:45:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.